Compositions and methods for treating hypophosphatasia

a technology of phosphatasia and compositions, applied in the field of compositions and methods for treating hypophosphatasia, can solve the problems of insufficient clinical improvement of plasma infusions of tnsalp, no definitive treatment is currently available, and defective bone mineralization, etc., to achieve the effect of increasing body weight and increasing life span

Inactive Publication Date: 2007-04-12
SAINT LOUIS UNIVERSITY +2
View PDF3 Cites 52 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021] Administration of the purified anchorless rhTNSALP enzyme into TNSALP knockout mice increased life span and increased body weight, showing that the treated mice lived approximately 4 and 7 times longer compared to the untreated mice. Treated mice had no epileptic seizures until at least 3 months old.

Problems solved by technology

Hypophosphatasia, caused by deficient activity of TNSALP results in defective bone mineralization.
Plasma infusions of TNSALP have not achieved clinical improvement.
No definitive treatment is presently available.
Enzyme replacement therapy for hypophosphatasia was not thought to be feasible since TNSALP exists as a membrane-bound enzyme and functions physiologically when the enzyme is present at the cell membrane.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for treating hypophosphatasia
  • Compositions and methods for treating hypophosphatasia
  • Compositions and methods for treating hypophosphatasia

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation and Biochemical Characterization of Enzymes

[0063] The GPI anchoring signal peptide 19 amino acid (SEQ:1 residues 506-524) sequence was removed from the C-terminal of the human TNSALP cDNA (SEQ:1) to release the enzyme in the media of CHO—K1 cells. (FIG. 1). The resultant anchorless rhTNSALP enzyme (>95%) was mainly secreted to culture medium in a transient expression study (data is not shown). Acidic oligopeptide-tagged enzymes (CD6-TNSALP and CD8-TNSALP), which also lack the GPI anchoring signal peptide, were secreted in to the culture medium as well. Constructs for the CD6- to CD8-TNSALP cDNA were made and transfected into CHO—K1 cells for transient expression. Cells stably expressed and secreted active TNSALP enzymes into the medium in linear fashion for 12 h. However expression of enzyme plateaued after 12 hours. The inventor's previous work with oligopeptide-tagged enzymes showed that increasing the number of Aspartic acid residues beyond eight caused a substantial...

example 2

Characteristics of Poly-Aspartic Acid—Tagged Anchorless rhTNSALP

Affinity for Hydroxyapatite

[0067] A remarkable difference between the tagged and untagged enzymes was observed in their affinity to hydroxyapatite. Affinity to hydroxyapatite for the tagged enzymes was 10-fold higher than that for the untagged enzyme and the binding to hydroxyapatite was seen even at low concentration of the tagged enzyme (FIG. 3). The binding parameters, Kb and Bmax, are shown in Table 4. The values of Kb and Bmax of the tagged enzymes were 10- and 3-fold, respectively, higher than those of the untagged enzyme. Although no significant difference was observed between CD6- and CD8-TNSALP.

TABLE 4Binding parameters of three enzymes to hydroxyapatite. Each valuerepresents the mean ± S.D. of 3 experiments. Kb binding constantand Bmax maximum binding rates were determined form double-reciprocal plots.KbBmax (ug / 100 ug(ug−1 ml)hydroxyapatite)rhTNSALP 1.7 ± 1.00.5 ± 0.2CD6-TNSALP36.7 ± 7.91.6 ± 0.3CD8-TNSA...

example 3

Effect of Anchorless rhTNSALP on Mineralization in the Presence of PPi in Primary Bone Marrow Cell Culture

[0072] In human bone marrow cells derived from a hypophosphatasia patient, mineralization never occurred in the absence of TNSALP even when β-glycerophosphate was added. The addition of one of the enzyme resulted in marked recovery of mineralization (FIG. 9). In contrast, mineralization was observed when Pi was used in the medium instead of β-glycerophosphate even in the absence of any enzyme. The presence of any of the enzymes did not provide any additive effect for the mineralization. These findings indicate that the anchorless rhTNSALP enzyme played a biological role in the mineralization process by providing free Pi released during the hydrolysis of β-glycerophosphate. We added PPi, an inhibitor of mineralization, to see whether the anchorless rhTNSALP enzyme hydrolyze PPi to restore the mineralization. PPi itself completely inhibited the mineralization even in the presence...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
molecular massaaaaaaaaaa
timeaaaaaaaaaa
Login to view more

Abstract

The present invention provides compositions and methods for use in enzyme replacement therapy. The inventors disclose a method of producing membrane bound enzymes in an active soluble form by eliminating the glycosylphosphatidylinositol (GPI) membrane anchor. In particular the inventors disclose a soluble active form of the membrane bound enzyme TNSALP which they produced by deleting the GPI anchor single peptide sequence. They have further shown that this composition is useful for treatment of hypophosphatasia. The inventors also disclose oligo acid amino acid variants thereof which specifically target bone tissue.

Description

PARENT CASE TEXT [0001] This application claims benefit of priority to U.S. Provisional Patent Application No. 60 / 725,563, filed Oct. 11, 2005.SEQUENCE LISTING [0002] A paper copy of the sequence listing and a computer readable form of the same sequence listing are appended below and herein incorporated by reference. The information recorded in computer readable form is identical to the written sequence listing, according to 37 C.F.R. 1.821(f). BACKGROUND OF THE INVENTION [0003] 1. Field of the Invention [0004] This invention relates generally to compositions and methods of enzyme replacement therapy (ERT). More specifically, the invention is directed to compositions and methods for treatment of enzyme deficient disease such as hypophosphatasia using a genetically modified polynucleotide to produce in an active secretory form of alkaline phosphatase. [0005] 2. Description of the Related Art [0006] Alkaline phosphatase (ALP) is a ubiquitous plasma membrane-bound enzyme. [0007] Hypoph...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00A61K38/46
CPCA61K38/465C12Y301/03001A61P19/00A61P19/08A61P3/00
Inventor TOMATSU, SHUNJISLY, WILLIAM S.GRUBB, JEFFREY H.NISHIOKA, TATSUOMIYAMOTO, KEN-ICHIYAMAGUCHI, SEIJI
Owner SAINT LOUIS UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap